Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Technical advance

Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer

Authors: Hannah Jörißen, Nuran Bektas, Edgar Dahl, Arndt Hartmann, Anette ten Haaf, Stefano Di Fiore, Hans Kiefer, Andreas Thess, Stefan Barth, Torsten Klockenbring

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

RAI3 is an orphan G-protein coupled receptor (GPCR) that has been associated with malignancy and may play a role in the proliferation of breast cancer cells. Although its exact function in normal and malignant cells remains unclear and evidence supporting its role in oncogenesis is controversial, its abundant expression on the surface of cancer cells would make it an interesting target for the development of antibody-based therapeutics. To investigate the link with cancer and provide more evidence for its role, we carried out a systematic analysis of RAI3 expression in a large set of human breast cancer specimens.

Methods

We expressed recombinant human RAI3 in bacteria and reconstituted the purified protein in liposomes to raise monoclonal antibodies using classical hybridoma techniques. The specific binding activity of the antibodies was confirmed by enzyme-linked immunosorbent assay (ELISA), western blot and immunocytochemistry. We carried out a systematic immunohistochemical analysis of RAI3 expression in human invasive breast carcinomas (n = 147) and normal breast tissues (n = 44) using a tissue microarray. In addition, a cDNA dot blot hybridisation assay was used to investigate a set of matched normal and cancerous breast tissue specimens (n = 50) as well as lymph node metastases (n = 3) for RAI3 mRNA expression.

Results

The anti-RAI3 monoclonal antibodies bound to recombinant human RAI3 protein with high specificity and affinity, as shown by ELISA, western blot and ICC. The cDNA dot blot and immunohistochemical experiments showed that both RAI3 mRNA and RAI3 protein were abundantly expressed in human breast carcinoma. However, there was no association between RAI3 protein expression and prognosis based on overall and recurrence-free survival.

Conclusion

We have generated a novel, highly-specific monoclonal antibody that detects RAI3 in formaldehyde-fixed paraffin-embedded tissue. This is the first study to report a systematic analysis of RAI3 expression in normal and cancerous human breast tissue at both the mRNA and protein levels.
Appendix
Available only for authorised users
Literature
1.
go back to reference Li S, Huang S, Peng SB: Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol. 2005, 27 (5): 1329-1339.PubMed Li S, Huang S, Peng SB: Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol. 2005, 27 (5): 1329-1339.PubMed
2.
go back to reference McCudden CR, Hains MD, Kimple RJ, Siderovski DP, Willard FS: G-protein signaling: back to the future. Cell Mol Life Sci. 2005, 62 (5): 551-577. 10.1007/s00018-004-4462-3.CrossRefPubMedPubMedCentral McCudden CR, Hains MD, Kimple RJ, Siderovski DP, Willard FS: G-protein signaling: back to the future. Cell Mol Life Sci. 2005, 62 (5): 551-577. 10.1007/s00018-004-4462-3.CrossRefPubMedPubMedCentral
3.
go back to reference Cheng Y, Lotan R: Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. J Biol Chem. 1998, 273 (52): 35008-35015. 10.1074/jbc.273.52.35008.CrossRefPubMed Cheng Y, Lotan R: Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. J Biol Chem. 1998, 273 (52): 35008-35015. 10.1074/jbc.273.52.35008.CrossRefPubMed
4.
go back to reference Robbins MJ, Michalovich D, Hill J, Calver AR, Medhurst AD, Gloger I, Sims M, Middlemiss DN, Pangalos MN: Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C). Genomics. 2000, 67 (1): 8-18. 10.1006/geno.2000.6226.CrossRefPubMed Robbins MJ, Michalovich D, Hill J, Calver AR, Medhurst AD, Gloger I, Sims M, Middlemiss DN, Pangalos MN: Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C). Genomics. 2000, 67 (1): 8-18. 10.1006/geno.2000.6226.CrossRefPubMed
5.
go back to reference Nagahata T, Sato T, Tomura A, Onda M, Nishikawa K, Emi M: Identification of RAI3 as a therapeutic target for breast cancer. Endocr Relat Cancer. 2005, 12 (1): 65-73. 10.1677/erc.1.00890.CrossRefPubMed Nagahata T, Sato T, Tomura A, Onda M, Nishikawa K, Emi M: Identification of RAI3 as a therapeutic target for breast cancer. Endocr Relat Cancer. 2005, 12 (1): 65-73. 10.1677/erc.1.00890.CrossRefPubMed
6.
go back to reference Wu Q, Ding W, Mirza A, Van Arsdale T, Wei I, Bishop WR, Basso A, McClanahan T, Luo L, Kirschmeier P, et al: Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. J Biol Chem. 2005, 280 (13): 12935-12943. 10.1074/jbc.M409901200.CrossRefPubMed Wu Q, Ding W, Mirza A, Van Arsdale T, Wei I, Bishop WR, Basso A, McClanahan T, Luo L, Kirschmeier P, et al: Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. J Biol Chem. 2005, 280 (13): 12935-12943. 10.1074/jbc.M409901200.CrossRefPubMed
7.
go back to reference Hirano M, Zang L, Oka T, Ito Y, Shimada Y, Nishimura Y, Tanaka T: Novel reciprocal regulation of cAMP signaling and apoptosis by orphan G-protein-coupled receptor GPRC5A gene expression. Biochemical and biophysical research communications. 2006, 351 (1): 185-191. 10.1016/j.bbrc.2006.10.016.CrossRefPubMed Hirano M, Zang L, Oka T, Ito Y, Shimada Y, Nishimura Y, Tanaka T: Novel reciprocal regulation of cAMP signaling and apoptosis by orphan G-protein-coupled receptor GPRC5A gene expression. Biochemical and biophysical research communications. 2006, 351 (1): 185-191. 10.1016/j.bbrc.2006.10.016.CrossRefPubMed
8.
go back to reference Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, et al: Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. Journal of the National Cancer Institute. 2007, 99 (22): 1668-1682. 10.1093/jnci/djm208.CrossRefPubMed Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, et al: Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. Journal of the National Cancer Institute. 2007, 99 (22): 1668-1682. 10.1093/jnci/djm208.CrossRefPubMed
9.
go back to reference Nagahata T, Onda M, Emi M, Nagai H, Tsumagari K, Fujimoto T, Hirano A, Sato T, Nishikawa K, Akiyama F, et al: Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray. Cancer science. 2004, 95 (3): 218-225. 10.1111/j.1349-7006.2004.tb02206.x.CrossRefPubMed Nagahata T, Onda M, Emi M, Nagai H, Tsumagari K, Fujimoto T, Hirano A, Sato T, Nishikawa K, Akiyama F, et al: Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray. Cancer science. 2004, 95 (3): 218-225. 10.1111/j.1349-7006.2004.tb02206.x.CrossRefPubMed
10.
go back to reference Kiefer H, Vogel R, Maier K: Bacterial expression of G-protein-coupled receptors: prediction of expression levels from sequence. Receptors Channels. 2000, 7 (2): 109-119.PubMed Kiefer H, Vogel R, Maier K: Bacterial expression of G-protein-coupled receptors: prediction of expression levels from sequence. Receptors Channels. 2000, 7 (2): 109-119.PubMed
11.
go back to reference Harris JF, Hawley RG, Hawley TS, Crawford-Sharpe GC: Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. Journal of immunological methods. 1992, 148 (1–2): 199-207. 10.1016/0022-1759(92)90173-Q.CrossRefPubMed Harris JF, Hawley RG, Hawley TS, Crawford-Sharpe GC: Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. Journal of immunological methods. 1992, 148 (1–2): 199-207. 10.1016/0022-1759(92)90173-Q.CrossRefPubMed
12.
go back to reference Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME: Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods. 1985, 77 (2): 305-319. 10.1016/0022-1759(85)90044-4.CrossRefPubMed Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME: Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods. 1985, 77 (2): 305-319. 10.1016/0022-1759(85)90044-4.CrossRefPubMed
13.
go back to reference Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Durst M, Klinkhammer-Schalke M: Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin α2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res. 2006, 12 (13): 3950-3960. 10.1158/1078-0432.CCR-05-2090.CrossRefPubMed Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Durst M, Klinkhammer-Schalke M: Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin α2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res. 2006, 12 (13): 3950-3960. 10.1158/1078-0432.CCR-05-2090.CrossRefPubMed
14.
go back to reference Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19 (5): 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19 (5): 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
16.
go back to reference Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe. 1987, 8 (3): 138-140.PubMed Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe. 1987, 8 (3): 138-140.PubMed
17.
go back to reference Lefkowitz RJ: Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol Sci. 2004, 25 (8): 413-422. 10.1016/j.tips.2004.06.006.CrossRefPubMed Lefkowitz RJ: Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol Sci. 2004, 25 (8): 413-422. 10.1016/j.tips.2004.06.006.CrossRefPubMed
18.
go back to reference Lagerstrom MC, Schioth HB: Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov. 2008, 7 (4): 339-357. 10.1038/nrd2518.CrossRefPubMed Lagerstrom MC, Schioth HB: Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov. 2008, 7 (4): 339-357. 10.1038/nrd2518.CrossRefPubMed
19.
go back to reference Kiefer H, Maier K, Vogel R: Refolding of G-protein-coupled receptors from inclusion bodies produced in Escherichia coli. Biochem Soc Trans. 1999, 27 (6): 908-912.CrossRefPubMed Kiefer H, Maier K, Vogel R: Refolding of G-protein-coupled receptors from inclusion bodies produced in Escherichia coli. Biochem Soc Trans. 1999, 27 (6): 908-912.CrossRefPubMed
20.
go back to reference Kiefer H: In vitro folding of alpha-helical membrane proteins. Biochim Biophys Acta. 2003, 1610 (1): 57-62. 10.1016/S0005-2736(02)00717-4.CrossRefPubMed Kiefer H: In vitro folding of alpha-helical membrane proteins. Biochim Biophys Acta. 2003, 1610 (1): 57-62. 10.1016/S0005-2736(02)00717-4.CrossRefPubMed
21.
go back to reference Stern DF, Heffernan PA, Weinberg RA: p185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. 1986, 6: 1729-1740. Stern DF, Heffernan PA, Weinberg RA: p185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. 1986, 6: 1729-1740.
23.
go back to reference Brockmann R, Beyer A, Heinisch J, Wilhelm T: Posttranscriptional Expression Regulation: What Determines Translation Rates?. PLoS Computational Biology. 2007, 3 (3): e57-10.1371/journal.pcbi.0030057.CrossRefPubMedPubMedCentral Brockmann R, Beyer A, Heinisch J, Wilhelm T: Posttranscriptional Expression Regulation: What Determines Translation Rates?. PLoS Computational Biology. 2007, 3 (3): e57-10.1371/journal.pcbi.0030057.CrossRefPubMedPubMedCentral
24.
go back to reference Hartung T, Balls M, Bardouille C, Blanck O, Coecke S, Gstraunthaler G, Lewis D: Good Cell Culture Practice. ECVAM Good Cell Culture Practice Task Force Report 1. Altern Lab Anim. 2000, 30: 407-414. Hartung T, Balls M, Bardouille C, Blanck O, Coecke S, Gstraunthaler G, Lewis D: Good Cell Culture Practice. ECVAM Good Cell Culture Practice Task Force Report 1. Altern Lab Anim. 2000, 30: 407-414.
25.
go back to reference Ye X, Lotan R: Potential misinterpretation of data on differential gene expression in normal and malignant cells in vitro. Brief Funct Genomic Proteomic. 2008, 7 (4): 322-6. 10.1093/bfgp/eln021.CrossRefPubMed Ye X, Lotan R: Potential misinterpretation of data on differential gene expression in normal and malignant cells in vitro. Brief Funct Genomic Proteomic. 2008, 7 (4): 322-6. 10.1093/bfgp/eln021.CrossRefPubMed
Metadata
Title
Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer
Authors
Hannah Jörißen
Nuran Bektas
Edgar Dahl
Arndt Hartmann
Anette ten Haaf
Stefano Di Fiore
Hans Kiefer
Andreas Thess
Stefan Barth
Torsten Klockenbring
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-200

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine